Clinical context
Myopia studies should distinguish refractive change from axial elongation. The measures are related but not interchangeable, and their clinical meaning depends on age, baseline myopia and follow-up duration. Studies of progression control should also assess tolerability, adherence, rebound after treatment stops and potential adverse effects.
What was studied
This systematic review and meta-analysis included randomized, nonrandomized and observational studies of adults receiving a posterior chamber phakic IOL. PubMed, Scopus, WANFANG and CNKI were searched through May 2024 without language or date restrictions. The primary outcome was explantation; secondary outcomes included rotation or displacement, cataract, glaucoma, endothelial failure, retinal detachment, macular edema, infection and other complications. Rates were modeled as events per 1,000 person-years.
How the evidence was produced
A meta-analysis combines several studies and can increase the precision of an overall estimate. Its conclusion still depends on the quality of the component studies, comparability of interventions and endpoints, statistical heterogeneity and publication bias. The pooled effect should be read with its confidence interval, sensitivity analyses and the reasons results differed across studies.
How to interpret the result
The large evidence base supports the conclusion that vision-threatening events are uncommon after contemporary posterior chamber phakic IOL implantation. A low average rate does not remove individual risk or the need for surveillance. The authors connect the findings to early assessment of centration, axis and vault and to long-term monitoring of the endothelium and anterior segment. The five-year translation assumes a constant hazard; it is not a direct result from one five-year cohort.
The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.
Clinical applicability
The findings apply most directly to patients who resemble participants in age, baseline refraction and rate of progression. Before selecting an intervention, check durability, the method used to measure axial length, completeness of follow-up and safety. A group average cannot predict the exact response of an individual child or adult.
Limitations
Most studies had short follow-up and a high risk of bias, so late complications were probably underestimated. The dominance of the V4c model limits generalization to other designs and generations. Regional differences may reflect patient selection, follow-up practice or reporting completeness rather than biology. The full article should be checked for heterogeneity, complication definitions, person-year denominators, analyses by follow-up duration and the influence of publication bias.
Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.
What to verify in the source
In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.